Aferrix Ltd.

Cabantchik Ioav, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences
Domb Abraham, HUJI, School of Medicine - IMRIC, School of Pharmacy- Institute for Drug Research
Breuer William, HUJI, Faculty of Science, The Alexander Silberman Institute for Life Sciences
Bentolila Alfonso, HUJI

Company Name


Company Founders

Prof. Zvi Ioav Cabantchik,

Current CEO

Yael Furman, Ms.C., MBA, CEO

About the Company

Aferrix is an innovative leader in development and applications of novel tools for early diagnosis and monitoring of toxic iron in the serum. The company has developed several methods that quantify different forms of toxic iron in the serum, which are not detected by conventional tests.

Aferrix offers iron testing services and kits for research and treatment centers that specialize in iron over load diseases (Thalassemia, Hemochromatosis, Myelodysplastic syndrome) and to pharmaceutical companies that are developing iron chelators.

Links to Products


Company Website


 Media Links

  • The Labile Side of Iron Supplementation in CKD 
     Read more…
  • Labile Iron: Potential Toxicity in Iron Overload Disorders
     Read more…
  • Assessment of Labile Plasma Iron in patient who undergo Heamatopoetic Stem Cell Transplantation 
     Read more…
  • Cabantchik Z V et al., The molecular and cellular basis of iron toxicity in iron overload disorders. Diagnostics the therapeutic approaches. Thalassemia reports , 2013, V.3(S1):e3. 
     Read more…
  • Berdoukas V et al. Non-transferrin bound iron revisited: now that it's potential toxicity has been established, how can its measurements help guide chelation. Poster presentation at the 2014 European Hematology Association conference.
     Read more…
  • Cabantchik V., Labile Iron in cell and body fluids: physiology, pathology and pharmacology, Frontiers in Pharmacology, review article, March 2014
     Read more…
  • Danjou et al, A decisional algorithm to start iron chelation in patients with beta Thalassemia,Hematologica, 2014, 99:e38.
     Read more…

Contact for more information:

Mel Larrosa
VP Business Development Healthcare